Anti-C-Reactive Protein/CRP antibody

Anti-C-Reactive Protein/CRP antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit polyclonal to C-Reactive Protein/CRP

ELISA, WB

Mouse C-reactive / CRP

CRP antibody; AI255847 antibody; C-Reactive Protein antibody; C-Reactive Protein antibody; CRP antibody; MGC149895 antibody; MGC88244 antibody; pentraxin 1 antibody; PTX1 antibody; RP11-419N10.4 antibody; PTX1 antibody; AI255847 antibody

Rabbit IgG

Produced in rabbits immunized with purified, recombinant Mouse CRP (rM CRP; NP_031794.3; Met 1-Ser 225). CRP IgG was purified by mouse CRP affinity chromatography

Polyclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

C-reactive protein (CRP) is synthesized by the liver in response to factors released by fat cells. It is a member of the pentraxin family of proteins. The levels of CRP rise in response to inflammation. Human C-reactive protein (CRP) is the classical acute phase reactant, the circulating concentration of which rises rapidly and extensively in a cytokine-mediated response to tissue injury, infection and inflammation. Serum CRP values are routinely measured, empirically, to detect and monitor many human diseases. However, CRP is likely to have important host defence, scavenging and metabolic functions through its capacity for calcium-dependent binding to exogenous and autologous molecules containing phosphocholine (PC) and then activating the classical complement pathway. CRP may also have pathogenic effects and the recent discovery of a prognostic association between increased CRP production and coronary atherothrombotic events is of particular interest.

• Pepys MB. et al., 2003, J Clin Invest. 111 (12): 1805-12.
• Thompson D. et al., 1999, Structure. 7(2): 169-77.